| Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum. | |
| | |
MedLine Citation:
|
PMID: 16891770 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p. per day selegiline for 7 days were administered with a single dose of 100 mg/kg, i.p. L-DOPA 0 (3 h), 1, 3, 7, 14, 21, or 28 days after the last selegiline treatment. Carbidopa was administered 0.5 h before L-DOPA administration. The significant increase in basal DA level before L-DOPA treatment persisted until 1 day after the last selegiline treatment, and the significant decrease in basal DOPAC level persisted for more than 28 days. Thus, selegiline affected DA catabolism for more than 28 days. Total monoamine oxidase (MAO) and MAO-B activities at day 0 decreased by 22% and 5.7%, respectively. The significant enhancement of L-DOPA-induced increase in DA level was observed until 3 days after the last selegiline treatment. Next, the effects of reducing L-DOPA dose by 25% were examined 3 h after the last selegiline treatment. A dose-dependent decrease in DA level was observed, indicating that DA level in selegiline-treated rats can be controlled by L-DOPA dose. |
| | |
Authors:
|
Kouichi Adachi; Hideto Miwa; Haruko Kusumoto; Seiichiro Shimazu; Tomoyoshi Kondo |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2006-08-05 |
Journal Detail:
|
Title: Journal of pharmacological sciences Volume: 101 ISSN: 1347-8613 ISO Abbreviation: J. Pharmacol. Sci. Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-08-21 Completed Date: 2006-10-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101167001 Medline TA: J Pharmacol Sci Country: Japan |
Other Details:
|
Languages: eng Pagination: 286-92 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Wakayama Medical University, Wakayama, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3,4-Dihydroxyphenylacetic Acid
/
metabolism Animals Corpus Striatum / drug effects*, enzymology, metabolism Dopamine / metabolism* Dose-Response Relationship, Drug Drug Administration Schedule Extracellular Space / drug effects, metabolism Homovanillic Acid / metabolism Injections, Intraperitoneal Levodopa / pharmacology* Male Microdialysis / methods Monoamine Oxidase / metabolism Monoamine Oxidase Inhibitors / administration & dosage, pharmacology Rats Rats, Sprague-Dawley Selegiline / administration & dosage, pharmacology* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Levodopa; 0/Monoamine Oxidase Inhibitors; 102-32-9/3,4-Dihydroxyphenylacetic Acid; 14611-51-9/Selegiline; 306-08-1/Homovanillic Acid; EC 1.4.3.4/Monoamine Oxidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: First phase of glucose-stimulated insulin secretion from MIN 6 cells does not always require extrace...
Next Document: Disturbance of response to acute thermal pain in naturally occurring cholecystokinin-a receptor gene...